NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Immorna Biotherapeutics

Immorna Biotherapeutics

Private
HangzhouHealthcare & Life Scienceshttps://www.immornabio.com/

Last Round

Grant

Aug 26, 2024

Total Funding Raised

$118.8M

Company Overview

Immorna Biotherapeutics is a biotechnology company that develops RNA-based therapeutics and vaccines for infectious diseases, cancer, and autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share, Government Contracts

AI Layer

Application

Keywords

mRNA therapeuticsRNA platformself-replicating RNAsrRNAcircular RNAcircRNAmRNA vaccinesRNA medicinesLNP drug deliveryplatform biotechdrug discoveryoncologyinfectious diseaserare diseaseCDMO servicesAI drug discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Immorna Biotherapeutics Comparables

Compare Immorna Biotherapeutics with similar companies based on industry and business-model similarity.

Immorna Biotherapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Innorna
90%
Orna Therapeutics
87%
Stemirna Therapeutics
85%

Immorna Biotherapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 26, 2024
Series A ExtensionFeb 27, 2023
Series AFeb 1, 2021

Immorna Biotherapeutics Investors

Notable investors and investment history

Immorna Biotherapeutics investors
InvestorRounds
Alwin CapitalPre Seed
China Chengtong Fund Management Co., Ltd.Series A Extension
Zheshang Venture CapitalSeries A Extension, Series A
Hillhouse InvestmentSeries A Extension
Co-Win VenturesSeries A Extension, Series A
Tailong InvestmentSeries A Extension
Tigeryeah CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2024

    $3.8M grant from the Bill & Melinda Gates Foundation.

  • Feb 27, 2023

    $100M round with participation from China Structural Reform Fund and Hillhouse Investment.

Immorna Biotherapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Immorna Biotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Immorna Biotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou
Year Founded2019
Last FundingAug 26, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.